Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.
作者信息
Wilson Andrew J, Troy-Barnes Ethan, Subhan Maryam, Clark Fiona, Gupta Rajeev, Fielding Adele K, Kottaridis Panagiotis, Mansour Marc R, O'Nions Jenny, Payne Elspeth, Chavda Naina, Baker Robert, Thomson Kirsty, Khwaja Asim
机构信息
Department of Haematology, University College London Hospital (UCLH), London, UK.
UCLH Specialist Integrated Haematology Malignancy Diagnostic Service, Health Services Laboratories, London, UK.
出版信息
Br J Haematol. 2020 Aug;190(4):e189-e191. doi: 10.1111/bjh.16962. Epub 2020 Jul 19.
Abstract
摘要
相似文献
1
Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.吉瑞替尼成功诱导一名初发FLT3突变急性髓系白血病合并重症COVID-19患者缓解
Br J Haematol. 2020 Aug;190(4):e189-e191. doi: 10.1111/bjh.16962. Epub 2020 Jul 19.
2
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.吉瑞替尼对复发或难治性急性髓系白血病中FLT3的选择性抑制作用：一项多中心、首例人体、开放标签的1-2期研究。
Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20.
3
Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study.FMS样酪氨酸激酶3抑制剂吉列替尼用于FMS样酪氨酸激酶3内部串联重复急性髓系白血病患者的维持治疗：一项2期研究。
Cancer. 2025 Feb 15;131(4):e35746. doi: 10.1002/cncr.35746.
4
Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.吉特替尼治疗复发和/或难治性 FLT3 突变型急性髓系白血病。
Expert Rev Clin Pharmacol. 2019 Sep;12(9):841-849. doi: 10.1080/17512433.2019.1657009. Epub 2019 Aug 27.
5
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.吉特替尼在既往接受 FLT3 抑制剂治疗的复发/难治性 FLT3 突变急性髓系白血病中的临床活性。
Am J Hematol. 2022 Mar 1;97(3):322-328. doi: 10.1002/ajh.26447. Epub 2022 Jan 7.
6
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a mutation.吉特替尼用于治疗携带 突变的复发或难治性急性髓系白血病。
Future Oncol. 2021 Jan;17(2):215-227. doi: 10.2217/fon-2020-0700. Epub 2020 Sep 25.
7
Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.同种异体二次移植后接受吉特替尼治疗后，FLT3-ITD AML 移植后复发患者获得持久缓解。
Int J Hematol. 2020 Aug;112(2):249-253. doi: 10.1007/s12185-020-02858-1. Epub 2020 Mar 17.
8
Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.异基因造血干细胞移植后伴 FLT3-ITD 突变的急性髓系白血病髓外孤立复发采用吉特替尼治疗获得成功。
Int J Hematol. 2020 Aug;112(2):243-248. doi: 10.1007/s12185-020-02855-4. Epub 2020 Mar 13.
9
Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.吉特替尼与化疗用于治疗复发/难治性 - 突变型 AML。
N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.
10
[Efficacy and safety of gilteritinib combined with chemotherapy in newly diagnosed FLT3-mutated acute myeloid leukemia].吉瑞替尼联合化疗治疗新诊断的FLT3突变型急性髓系白血病的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2024 Dec 14;45(12):1129-1133. doi: 10.3760/cma.j.cn121090-20240615-00224.
引用本文的文献
1
SARS-CoV-2 mechanisms of cell tropism in various organs considering host factors.考虑宿主因素的SARS-CoV-2在各器官中的细胞嗜性机制。
Heliyon. 2024 Feb 20;10(4):e26577. doi: 10.1016/j.heliyon.2024.e26577. eCollection 2024 Feb 29.
2
Acute necrotizing encephalopathy in children with COVID-19: a retrospective study of 12 cases.新型冠状病毒肺炎患儿的急性坏死性脑病：12例回顾性研究
Front Neurol. 2023 Aug 2;14:1184864. doi: 10.3389/fneur.2023.1184864. eCollection 2023.
3
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.重新利用临床可用药物和疗法针对致病靶点来对抗新型冠状病毒。
MedComm (2020). 2023 May 14;4(3):e254. doi: 10.1002/mco2.254. eCollection 2023 Jun.
4
Gas6/TAM Axis Involvement in Modulating Inflammation and Fibrosis in COVID-19 Patients.Gas6/TAM 轴在调节 COVID-19 患者炎症和纤维化中的作用。
Int J Mol Sci. 2023 Jan 4;24(2):951. doi: 10.3390/ijms24020951.
5
Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice.伊布替尼通过靶向 BTK、FLT3 和 EGFR 预防小鼠急性肺损伤。
Int J Mol Sci. 2022 Nov 3;23(21):13478. doi: 10.3390/ijms232113478.
6
Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.靶向激酶抑制剂抗 SARS-CoV-2 活性：将临床可用药物重新用于 COVID-19 治疗。
J Med Virol. 2023 Jan;95(1):e28157. doi: 10.1002/jmv.28157. Epub 2022 Sep 28.
7
Recent clinical findings on the role of kinase inhibitors in COVID-19 management.近期关于激酶抑制剂在 COVID-19 管理中作用的临床发现。
Life Sci. 2022 Oct 1;306:120809. doi: 10.1016/j.lfs.2022.120809. Epub 2022 Jul 13.
8
Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy.FLT3+急性髓系白血病患者的治疗管理：病例报告及对吉列替尼单药治疗的关注
Pharmgenomics Pers Med. 2022 Apr 22;15:393-407. doi: 10.2147/PGPM.S346688. eCollection 2022.
9
COVID 19 and febrile neutropenia: Case report and systematic review.COVID-19 与发热性中性粒细胞减少症：病例报告和系统评价。
Travel Med Infect Dis. 2022 May-Jun;47:102305. doi: 10.1016/j.tmaid.2022.102305. Epub 2022 Mar 7.
10
Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo.基于大规模体外筛选和体内药效评价发现抗 SARS-CoV-2 药物。
Sci China Life Sci. 2022 Jun;65(6):1181-1197. doi: 10.1007/s11427-021-2031-7. Epub 2021 Dec 24.
本文引用的文献
1
Treating Leukemia in the Time of COVID-19.在 COVID-19 期间治疗白血病。
Acta Haematol. 2021;144(2):132-145. doi: 10.1159/000508199. Epub 2020 May 11.
2
Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies.新冠病毒病与血液系统恶性肿瘤并存的住院患者生存研究
Br J Haematol. 2020 Jul;190(1):e16-e20. doi: 10.1111/bjh.16801. Epub 2020 May 27.
3
COVID-19 in persons with haematological cancers.COVID-19 与血液系统恶性肿瘤。
Leukemia. 2020 Jun;34(6):1637-1645. doi: 10.1038/s41375-020-0836-7. Epub 2020 Apr 24.
4
Gilteritinib: potent targeting of FLT3 mutations in AML.吉特替尼：针对 AML 中 FLT3 突变的有效靶向治疗。
Blood Adv. 2020 Mar 24;4(6):1178-1191. doi: 10.1182/bloodadvances.2019000174.
5
Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.吉特替尼与化疗用于治疗复发/难治性 - 突变型 AML。
N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.
6
Risk of bacteraemia and mortality in patients with haematological malignancies.血液系统恶性肿瘤患者发生菌血症及死亡的风险
Clin Microbiol Infect. 2006 Mar;12(3):217-23. doi: 10.1111/j.1469-0691.2005.01298.x.
Zotero 插件